America and Britain Establish Tariff-Free Accord on Medicines.

The United Kingdom and the United States have hammered out a key commercial pact that will maintain zero levies on British drug shipments being sold in the American market.

The Terms of the Accord

Under the terms of the agreement, the UK has committed to raise funding on medicines through the National Health Service (NHS). This move ensures that duties on these key goods will remain at zero for a period of 36 months.

This deal is in response to recent statements to dramatically increase duties on branded pharmaceutical imports, with increases discussed up to double the cost.

"This agreement between the UK reinforces the worldwide climate for innovative medicines and establishes much-needed fairness to transatlantic drug exports," a release said.

Commercial Significance

Medicines represent one of the UK's most significant export categories to the United States, which is clearly the primary destination for large companies like GSK and AstraZeneca.

Statistics indicate that in the year leading up to last September, the UK sold medicines worth billions to the US. This amount made up 17.4% of British export trade in that period.

"This guarantee safeguards work, stimulates capital expenditure and sets the stage for the UK to emerge as a international leader for medical research," the Business and Trade Secretary commented.

Key NHS Changes

The pact entails several specific changes from the British government:

• Revised Affordability Limit: The UK will increase the price threshold at which it considers new treatments to be unaffordable by a quarter.
• Boosted Medicine Funding: There is a target to increase overall NHS spending on medicines from 0.3% of Gross Domestic Product to 0.6 percent over the next decade.
• Rebate Cap: The sum manufacturers must pay back to the NHS to control costs will be restricted at fifteen percent. Previously, rebates topped twenty percent.

Industry Background

The deal comes amid a protracted tension between the pharmaceutical industry and the ministers over spending levels and NHS adoption.

This friction were heightened by assertions that US patients were paying several times more for the same drugs than consumers in the other developed nations.

Recently, several major pharmaceutical investments in the UK have been delayed or abandoned, while substantial investments have been directed toward US facilities.

The Science Minister acknowledged that the NHS had to increase expenditure on medicines, noting that its budget allocation on drugs had decreased as a proportion of its resources over the previous ten-year period.